Clinical Trials Browser

NIH × Hodgkin Disease × temsirolimus × Clear all

NCT01076543 2019-10-16

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone

NCT01902160 2015-11-09

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Completed

3 enrolled

Lymphoid

Hodgkin Disease

NCT00659568 2013-05-30

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Phase 1 Completed

28 enrolled

BreastDermatologicGenitourinaryGynecologicLymphoidOther hematologic neoplasmThoracic

Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Renal Cell, Hodgkin Disease, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Endometrial Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Small Cell Lung Carcinoma

NCT00086840 2013-01-24

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 2 Terminated

60 enrolled

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse